Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Alkermes plc ALKS

Healthcare Biotechnology
Alkermes plc is Ireland-based biopharmaceutical company that seeks to develop medicines in the field of neuroscience. The Company has a portfolio of commercial products for the treatment of alcohol dependence, opioid dependence, schizophrenia and bipolar I disorder and a pipeline of clinical and preclinical candidates in development for neurological disorders. It focuses on commercial products,... see more

Recent & Breaking News (NDAQ:ALKS)

Consolidated Research: 2018 Summary Expectations for Alkermes plc, Net 1 UEPS Technologies, CoreCivic, Inc., Videocon d2h, Shinhan Financial Group, and Himax Technologies — Fundamental Analysis, Key Performance Indications

GlobeNewswire April 10, 2018

SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Investors of an Investigation Involving Possible Securities Fraud Violations by the Board of Directors of Alkermes plc

Business Wire April 3, 2018

41 Biggest Movers From Yesterday

Benzinga.com  April 3, 2018

33 Stocks Moving In Monday's Mid-Day Session

Benzinga.com  April 2, 2018

Mid-Morning Market Update: Markets Open Lower; Cal-Maine Foods Posts Upbeat Sales

Benzinga.com  April 2, 2018

Alkermes Falls 20% After FDA Refusal To File Letter

Benzinga.com  April 2, 2018

Should you buy or sell stock in Alkermes, Alibaba, Las Vegas Sands, Under Armour and Walmart Stores?

PR Newswire April 2, 2018

28 Stocks Moving In Monday's Pre-Market Session

Benzinga.com  April 2, 2018

Alkermes Receives Refusal to File Letter From FDA for ALKS 5461

PR Newswire Europe Non Regulatory April 2, 2018

Alkermes' Corporate Presentation to be Webcast at Upcoming Healthcare Conferences

PR Newswire Europe Non Regulatory March 5, 2018

Alkermes Appoints James Robinson as President and Chief Operating Officer

PR Newswire Europe Non Regulatory March 1, 2018

The Market In 5 Minutes: Jobless Claims Fall, 10-Year Treasury Yields, Twitter Makes Some Changes

Benzinga.com  February 22, 2018

Alkermes Appoints Shane Cooke to Board of Directors

PR Newswire Europe Non Regulatory February 14, 2018

Alkermes plc Reports Financial Results for the Year Ended Dec. 31, 2017 and Provides Financial Expectations for 2018

PR Newswire Europe Non Regulatory February 14, 2018

Alkermes Plc to Host Earnings Call

Accesswire February 14, 2018

Alkermes To Host Conference Call To Discuss Fourth Quarter And Year-End 2017 Financial Results

PR Newswire Europe Non Regulatory February 7, 2018

Alkermes Submits New Drug Application To U.S. FDA For ALKS 5461 For The Adjunctive Treatment Of Major Depressive Disorder

PR Newswire January 31, 2018

ALKERMES INVESTOR ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $100,000 In Alkermes plc To Contact The Firm

Business Wire January 17, 2018

FINAL DEADLINE ALERT: Brower Piven Reminds Shareholders Of Approaching Deadline In Class Action Lawsuit And Encourages Investors Who Have Losses In Excess Of $100,000 From Investment In Array BioPharma Inc. (Nasdaq: ARRY) To Contact The Firm

GlobeNewswire January 17, 2018

Scott+Scott, Attorneys at Law, LLP Reminds Investors of January 22 Deadline in Securities Class Action Against Alkermes plc (ALKS)

Business Wire January 17, 2018